INVESTABOT
Equity Research
XNYS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Johnson & Johnson (JNJ) had 1 Form 144 pre-sale notice filed on 2026-09-02. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Johnson & Johnson (JNJ) had 1 Form 144 pre-sale notice filed on 2026-08-17. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Johnson & Johnson (JNJ) had 1 Form 144 pre-sale notice filed on 2026-08-13. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Johnson & Johnson (JNJ) had 1 Form 144 pre-sale notice filed on 2026-08-06. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Johnson & Johnson (JNJ) had 1 Form 144 pre-sale notice filed on 2026-08-05. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
TL;DR: Johnson & Johnson announced that Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine, will retire after more than 21 years with the company, with Tom Cavanaugh stepping into…
Johnson & Johnson (JNJ) had 1 Form 144 pre-sale notice filed on 2026-07-20. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
TL;DR: Johnson & Johnson reported Q2 2026 sales of $25.3 billion, up 6.6% from the prior year, and raised its full-year revenue guidance to $101.1 billion — which would mark the first time in the company's 140-year…
Johnson & Johnson (JNJ) had 1 Form 144 pre-sale notice filed on 2026-06-11. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
open-market Form 4 only - grants, exercises, tax withholding excluded
0 buyers - 5 unique sellers · Institutional activity: not available - insufficient comparable institutions for the latest complete quarter.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| September 8, 2026 | Hewson Marillyn A | — | GRANT | 180.96 | $276 | ~$50K |
| September 8, 2026 | Woods Eugene A. | — | GRANT | 135.72 | $276 | ~$37K |
| September 8, 2026 | Pinto Daniel E | — | GRANT | 113.1 | $276 | ~$31K |
| September 2, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | OPTION_EXERCISE | 11,070 | $132 | ~$1.5M |
| September 2, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | SELL | -11,070 | $275 | ~$3.0M |
| September 2, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | OPTION_EXERCISE | 22,527 | $151 | ~$3.4M |
| September 2, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | SELL | -22,527 | $275 | ~$6.2M |
| September 2, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | OPTION_EXERCISE | -11,070 | — | — |
| September 2, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | OPTION_EXERCISE | -22,527 | — | — |
| August 17, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | OPTION_EXERCISE | 15,000 | $116 | ~$1.7M |
| August 17, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | SELL | -15,000 | $263 | ~$4.0M |
| August 17, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | OPTION_EXERCISE | -15,000 | — | — |
| August 13, 2026 | Duato Joaquin | CEO and Chairman of the Board | OPTION_EXERCISE | 123,291 | $116 | ~$14.3M |
| August 13, 2026 | Duato Joaquin | CEO and Chairman of the Board | SELL | -20,976 | $262 | ~$5.5M |
| August 13, 2026 | Duato Joaquin | CEO and Chairman of the Board | SELL | -102,315 | $261 | ~$26.7M |
| August 13, 2026 | Duato Joaquin | CEO and Chairman of the Board | OPTION_EXERCISE | -123,291 | — | — |
| August 6, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | OPTION_EXERCISE | 9,344 | $132 | ~$1.2M |
| August 6, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | SELL | -9,344 | $258 | ~$2.4M |
| August 6, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | SELL | -6,574 | $256 | ~$1.7M |
| August 6, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | OPTION_EXERCISE | -9,344 | — | — |
| Date | Filer | Relationship | Est. shares | Filing |
|---|---|---|---|---|
| September 2, 2026 | Schmid Timothy | — | 33,597 | SEC |
| August 17, 2026 | Taubert Jennifer L | — | 15,000 | SEC |
| August 13, 2026 | Duato Joaquin | — | 123,291 | SEC |
| August 6, 2026 | Forminard Elizabeth | — | 15,918 | SEC |
| August 5, 2026 | J.P. Morgan Securities LLC as agent and attorney-in-fact for Joaquin Duato | — | — | SEC |
| July 20, 2026 | Broadhurst Vanessa | — | 23,054 | SEC |
| June 11, 2026 | Wengel Kathryn E | — | 10,000 | SEC |
| Date | Insider | Title | Relationship | Shares | Filing |
|---|---|---|---|---|---|
| September 1, 2026 | — | — | — | — | SEC |